The estimated Net Worth of William E. Rote is at least $1.88 Million dollars as of 16 November 2020. William Rote owns over 2,500 units of Retrophin stock worth over $1,686 and over the last 8 years he sold RTRX stock worth over $567,033. In addition, he makes $1,310,230 as Senior Vice President and Head of Research and Development at Retrophin.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
William Rote RTRX stock SEC Form 4 insiders trading
William has made over 12 trades of the Retrophin stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,500 units of RTRX stock worth $59,900 on 16 November 2020.
The largest trade he's ever made was selling 5,000 units of Retrophin stock on 14 November 2018 worth over $120,150. On average, William trades about 1,476 units every 53 days since 2017. As of 16 November 2020 he still owns at least 24,086 units of Retrophin stock.
You can see the complete history of William Rote stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Rote biography
Dr. William E. Rote, Ph.D. is the Senior Vice President and Head of Research and Development of the Company. Previously, Dr. Rote led clinical development at Ardea Biosciences, a wholly owned subsidiary of AstraZeneca, serving as Vice President, Clinical Development from September 2014 to July 2016. From 2003 to 2014, Dr. Rote held numerous positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a biopharmaceutical company, including Vice President, Site Head for Research & Development from September 2012, to July 2014, Vice President, Research & Product Development from January 2010 to September 2012, and Vice President, Corporate Development, New Ventures, from 2007 to 2010, among others. From 1993 to 2003, Dr. Rote served as Executive Director, Development of Corvas International, a biopharmaceutical company. He earned both his Ph.D. in Pharmacology and B.S. in Pre-Medicine from Pennsylvania State University, and received postdoctoral training from the University of Michigan.
What is the salary of William Rote?
As the Senior Vice President and Head of Research and Development of Retrophin, the total compensation of William Rote at Retrophin is $1,310,230. There are 4 executives at Retrophin getting paid more, with Eric Dube having the highest compensation of $9,679,320.
How old is William Rote?
William Rote is 57, he's been the Senior Vice President and Head of Research and Development of Retrophin since 2017. There are 4 older and 10 younger executives at Retrophin. The oldest executive at Retrophin, Inc. is Gary Lyons, 68, who is the Independent Chairman of the Board.
What's William Rote's mailing address?
William's mailing address filed with the SEC is C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO, CA, 92130.
Insiders trading at Retrophin
Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer, and Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.
What does Retrophin do?
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
What does Retrophin's logo look like?
Complete history of William Rote stock trades at Retrophin
Retrophin executives and stock owners
Retrophin executives and other stock owners filed with the SEC include:
-
Eric Dube,
President, Chief Executive Officer, Director -
Elizabeth Reed,
Senior Vice President, General Counsel and Corporate Secretary -
Noah Rosenberg,
Chief Medical Officer -
Peter Heerma,
Chief Commercial Officer -
William Rote,
Senior Vice President and Head of Research and Development -
Laura Clague,
Chief Financial Officer, Senior Vice President -
Stephen Aselage,
Director -
Sandra Poole,
Independent Director -
Gary Lyons,
Independent Chairman of the Board -
Timothy Coughlin,
Independent Director -
Jeffrey Meckler,
Independent Director -
John Orwin,
Independent Director -
Roy Baynes,
Independent Director -
Ron Squarer,
Independent Director -
Suzanne Bruhn,
Independent Director -
Neil F. Mc Farlane,
Chief Operating Officer -
Jensen Margaret E Valeur,
General Counsel -
John W Kozarich,
Director -
Alvin Shih,
EVP of Research & Development -
Cornelius E Golding,
Director -
Steve Aselage,
Director -
Martin Shkreli,
Chief Executive Officer -
Steven Gary Richardson,
Director -
Horacio Plotkin,
Chief Medical Officer -
Jeffrey Paley,
Director -
Marc L Panoff,
Chief Financial Officer